We examined whether weekly DPP4 inhibitor omarigliptin (OMG) can improve liver function as well as levels of inflammation and insulin resistance in type 2 diabetic patients with non-alcoholic fatty liver disease (NAFLD). The gene discussed is DPP4; the disease is metabolic dysfunction-associated steatotic liver disease.